SYGNIS signs second non-exclusive distribution agreement for Asia with Welgene Biotech Co., Ltd. in Taiwan
- Welgene Biotech is a leading life science distributor focused on molecular biology and cell biology
- TruePrime™ and SunScript™ product families comprise powerful tools addressing key challenges in next generation sequencing (NGS) and single cell analysis (SCA)
Madrid, Spain and Heidelberg, Germany, June 11th, 2015 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has signed a non- exclusive distribution agreement for the commercialization of SYGNIS’ proprietary product portfolio in Taiwan with Welgene Biotech.
Under the terms of the agreement, SYGNIS has granted Welgene Biotech the non- exclusive rights to promote, market and sell TruePrimeTM products for primer-free WGA as well as SunScript™ thermostable reverse transcriptase kits for the translation of RNA into DNA to scientists working in the wide field of molecular biology in Taiwan.
TruePrimeTM products are based on the combination of the recently discovered DNA primase “TthPrimPol” and the Phi29 polymerase, which allows the amplification of total genomic DNA from smallest amounts of samples down to single cells without the need of random synthetic primers.
SYGNIS’ SunScript™ product line covers a series of kits based on a novel proprietary engineered reverse transcriptase (RT) which today is one of the most thermostable and fastest enzymes commercially available. RTs are commonly used in molecular biology to convert genetic information from RNA molecules back to DNA, enabling a number of downstream analyses of RNA molecules using DNA analysis methods such as NGS or polymerase chain reaction (PCR) in gene expression profiling and molecular diagnostics.
Welgene Biotech is a specialist provider offering a broad portfolio of innovative research reagents and state-of-the-art instruments in the field of molecular biology as well as cell biology applications to customers in Taiwan.
“We are very pleased that we are able to announce the second distribution agreement in Asia with Welgene Biotech, which significantly strengthens our presence in the Asian market and perfectly position our products in the rapidly growing biotechnology industry in Taiwan,” Pilar de la Huerta, CEO and CFO of SYGNIS commented. “Welgene Biotech complements our fast growing list of leading international distribution partners. The high interest and demand in our proprietary product and technology families fuel our efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the molecular biology industry throughout the world.”
Beside the worldwide commercialization via a fast growing list of leading international distribution partners, the product portfolio can also be directly ordered through SYGNIS’ own online shop under http://www.sygnis.com/shop.
TruePrime™ is the brand name of a revolutionary novel multiple displacement amplification (MDA) technology and one of the key products in SYGNIS’ portfolio. TruePrimeTM is based on the combination of the recently discovered DNA primase “TthPrimPol” and the extremely processive and high-fidelity Phi29 polymerase to amplify uniformly total genomic DNA for a multitude of applications including next generation sequencing and single cell analysis. The extraordinary strand-displacement capacity of Phi29 polymerase allows TthPrimPol to generate new primers on the displaced strands that are extended by Phi29 DNA pol, resulting in exponential isothermal DNA amplification without the need of any synthetic random primers.
The resulting benefits of this innovative approach are enormous and include the complete absence of common artifacts linked to the use of oligonucleotides, a reduced amplification bias in genome coverage compared to methods using random synthetic primers, a surpassing reliability as contaminating DNA is not amplified and an exquisite reproducibility when DNA is amplified from single mammalian cells. Moreover, TruePrime™ shows superior sensitivity, is easy to use and works perfectly well with all commonly used NGS platforms such as Illumina and Ion Torrent.
About SunScript™ RT
SunScript™ Reverse Transcriptase is a reverse transcriptase that has been engineered for high thermostability, based on the well characterized human immunodeficiency virus RT (HIV-1 RT). The enzyme is active up to temperatures of 85°C. SunScriptTM Reverse Transcriptase will be available in two versions: SunScriptTM RT RNaseH+ is optimized for the synthesis of complementary DNA (cDNA) as well as for use in reverse transcriptase (RT) PCR and quantitative PCR reactions whereas SunScriptTM RT RNaseH- permits high yields of full length cDNA synthesis on long RNA molecules for the construction of cDNA libraries needed for example in next generation sequencing applications.
For further information please contact:
Pilar de la Huerta
Phone: +34 91 192 36 50
MC Services AG
Phone: +49 89 210228 30